Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis

H. Vaverková, D. Karásek, D. Novotný, D. Jackuliaková, J. Lukeš, M. Halenka, J. Frohlich

. 2009 ; 42 (12) : 1246-1251.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11022398

Grantová podpora
NR9068 MZ0 CEP - Centrální evidence projektů

OBJECTIVE: To characterize the differences in various risk factors for atherosclerosis between individuals with apoB higher (H) and lower (L) than predicted from regression equation apoB vs LDL-C. METHODS: We evaluated 391 dyslipidemic subjects not treated with hypolipidemic drugs. The measured parameters included lipid profile, apolipoproteins A-1 and B, markers of insulin resistance and inflammation/hemostasis. RESULTS: Correlation coefficient between apoB and LDL-C was 0.9 (p<0.0001). Individuals with H apoB compared to L apoB had significantly higher sex and age adjusted BMI, waist circumference, insulin, HOMA (fasting insulinglucose/22.5), C-peptide, proinsulin, PAI-1, sICAM-1, sVCAM-1, t-PA, vWF, frequency of metabolic syndrome and lower values of TC, LDL-C and HDL-C (p<0.05 to <0.001 for all parameters). CONCLUSION: Individuals with apoB higher than predicted by their LDL-C levels are more insulin resistant and have more atherogenic risk profile. Thus, at least for dyslipidemic patients with high cardiometabolic risk, apoB is a more appropriate marker of risk than LDL-C.

Citace poskytuje Crossref.org

000      
02630naa 2200433 a 4500
001      
bmc11022398
003      
CZ-PrNML
005      
20140228143544.0
008      
110729s2009 xxu e Eng||
009      
AR
024    __
$a 10.1016/j.clinbiochem.2009.05.004 $2 doi
035    __
$a (PubMed)19450572
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vaverková, Helena, $d 1942- $7 nlk20000083882
245    10
$a Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis / $c H. Vaverková, D. Karásek, D. Novotný, D. Jackuliaková, J. Lukeš, M. Halenka, J. Frohlich
314    __
$a 3rd Department of Internal Medicine, University Hospital Olomouc, Czech Republic. helena.vaverkova@fnol.cz
520    9_
$a OBJECTIVE: To characterize the differences in various risk factors for atherosclerosis between individuals with apoB higher (H) and lower (L) than predicted from regression equation apoB vs LDL-C. METHODS: We evaluated 391 dyslipidemic subjects not treated with hypolipidemic drugs. The measured parameters included lipid profile, apolipoproteins A-1 and B, markers of insulin resistance and inflammation/hemostasis. RESULTS: Correlation coefficient between apoB and LDL-C was 0.9 (p<0.0001). Individuals with H apoB compared to L apoB had significantly higher sex and age adjusted BMI, waist circumference, insulin, HOMA (fasting insulinglucose/22.5), C-peptide, proinsulin, PAI-1, sICAM-1, sVCAM-1, t-PA, vWF, frequency of metabolic syndrome and lower values of TC, LDL-C and HDL-C (p<0.05 to <0.001 for all parameters). CONCLUSION: Individuals with apoB higher than predicted by their LDL-C levels are more insulin resistant and have more atherogenic risk profile. Thus, at least for dyslipidemic patients with high cardiometabolic risk, apoB is a more appropriate marker of risk than LDL-C.
590    __
$a bohemika - dle Pubmed
650    _2
$a dospělí $7 D000328
650    _2
$a apolipoproteiny B $x krev $7 D001055
650    _2
$a nemoci koronárních tepen $x krev $7 D003324
650    _2
$a biomarkery farmakologické $x krev $7 D054316
650    _2
$a LDL-cholesterol $x krev $7 D008078
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a inzulinová rezistence $7 D007333
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metabolický syndrom $x krev $7 D024821
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rizikové faktory $7 D012307
650    _2
$a statistika jako téma $7 D013223
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Karásek, David $7 stk2007415300
700    1_
$a Novotný, Dalibor, $d 1965-2015 $7 xx0041926
700    1_
$a Jackuliaková, Dagmar $7 xx0101837
700    1_
$a Lukeš, Jiří $7 xx0070976
700    1_
$a Halenka, Milan $7 xx0047393
700    1_
$a Frohlich, Jiří, $d 1942- $7 xx0064831
773    0_
$t Clinical Biochemistry $w MED00001119 $g Roč. 42, č. 12 (2009), s. 1246-1251
910    __
$a ABA008 $b x $y 2 $z 0
990    __
$a 20110801153712 $b ABA008
991    __
$a 20140228143545 $b ABA008
999    __
$a ok $b bmc $g 881776 $s 732318
BAS    __
$a 3
BMC    __
$a 2009 $x MED00001119 $b 42 $c 12 $d 1246-1251 $m Clinical biochemistry $n Clin Biochem
GRA    __
$a NR9068 $p MZ0
LZP    __
$a 2011-4B09/jvme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé